JavaScript seem to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.
Research Grade Otelixizumab is a chimeric humanized monoclonal antibody which targets T-cell surface glycoprotein CD3 epsilon chain.